Skip to Main Content

Paper Details

Early cost-utility analysis of genetically guided therapy for patients with drug-resistant epilepsy.
Epilepsia
1
2022
antiseizure, drug, drug-resistant epilepsy, epilepsy, gene panels, genomic databases, patient, patients, pharmacogenomics panel, seizure
Author NameAffiliation
Nicola WaddellQIMR Berghofer Medical Research Institute
Nicola WaddellUniversity of Queensland
Nicola Waddell
Nicola WaddellQIMR Berghofer Medical Research Institute
Nicola WaddellUniversity of Queensland
Nicola Waddell
  • 1 - 6

Datasets

Release 1.2